Researchers led by UC Davis Well being scientist Sanchita Bhatnagar have developed a promising gene remedy that might deal with Rett syndrome. The remedy works on reactivating wholesome however silent genes liable for this uncommon dysfunction and presumably different X-linked circumstances, similar to fragile X syndrome.
Their findings have been revealed in Nature Communications.
About Rett syndrome
Rett syndrome is a genetic situation that impacts principally women. It’s attributable to a faulty MECP2 gene situated on the X chromosome. This gene comprises directions for the synthesis of MeCP2 protein.
Women with Rett syndrome could have too little of this protein or their protein could not work correctly. This protein deficiency could cause a variety of signs, together with lack of speech, impaired hand actions, respiration difficulties and seizures.
Silenced genes
Females have two X chromosomes (XX). In every cell, one X chromosome will randomly be silenced in a course of often called X chromosome inactivation (XCI). In women with Rett syndrome, the silenced chromosome carries a wholesome copy of MECP2.
Our examine checked out reactivating the silenced X chromosome carrying the wholesome gene. It confirmed that reactivating the gene is feasible and might reverse the signs.”
Sanchita Bhatnagar, Examine’s Senior Creator
Bhatnagar is an affiliate professor with the UC Davis Division of Medical Microbiology and Immunology and runs The Bhatnagar Laboratory. She is an assistant analysis program chief on the UC Davis Complete Most cancers Heart and a researcher on the MIND Institute.
Sponge-like molecules to beat microRNA’s silencing energy
The brand new examine did a genome-wide screening to establish small RNA molecules (microRNA) concerned in XCI and X-linked gene silencing. It discovered that microRNA-106a (miR-106a) was energetic in switching off X chromosomes and the MECP2 gene.
The staff examined if blocking miR-106a may weaken the silencing impact and “get up” the dormant wholesome gene. For that, they used a feminine mouse mannequin of Rett syndrome and a gene remedy vector developed by Professor Kathrin Meyer on the Nationwide Youngsters’s Hospital. The vector delivered a particular DNA-based molecule that acts as a “sponge” by attracting miR-106a. The molecule reduces the supply of miR-106a on the X chromosome, which gives a therapeutic window for gene activation and MeCP2 manufacturing.
Spectacular outcomes
The outcomes have been very spectacular: The handled mice lived longer and confirmed higher motion and cognition than the untreated ones. The examine additionally confirmed a major enchancment within the respiration irregularities of the handled mice.
“The diseased cell holds its personal treatment. With our know-how, we’re simply making it conscious of its skill to interchange the defective gene with a useful gene,” Bhatnagar defined. “Even a small quantity of this gene expression (activation) has therapeutic profit.”
Importantly, the Rett mouse mannequin dealt with the remedy properly.
“Our gene therapy-based method focusing on X chromosome silencing confirmed important enchancment of a number of signs of Rett syndrome,” Bhatnagar mentioned. “Women with Rett exhibit a variety of signs, restricted mobility and communication expertise. They’ve apnea and seizures. It might be life-changing if we may help reverse a few of their signs to allow them to communicate in the event that they’re hungry or stroll to get a drink. What if we will forestall these seizures and apnea episodes, or just scale back them?”
Rett syndrome nonetheless has no treatment. For households affected by Rett syndrome, this discovery brings some hope {that a} remedy may in the future change lives. This method may additionally work for related circumstances attributable to X-linked genes.
Earlier than transferring to scientific trials, the researchers have to conduct security research to additional consider the efficiency of the remedy and the fitting dosage.
Supply:
College of California – Davis Well being
Journal reference:
Lou, S., et al. (2025). Concentrating on microRNA-dependent management of X chromosome inactivation improves the Rett Syndrome phenotype. Nature Communications. doi.org/10.1038/s41467-025-61092-7.
